Internal link ProQR Announces First Quarter 2026 Operating and Financial Results Mai 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform Mai 11, 2026 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 Mai 04, 2026 at 12:00 PM UTC
Internal link ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors April 30, 2026 at 12:00 PM UTC
Internal link ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event April 08, 2026 at 08:00 PM UTC
Internal link ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board April 08, 2026 at 12:00 PM UTC
Internal link ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 März 25, 2026 at 12:00 PM UTC
Internal link ProQR Announces Year End 2025 Operating and Financial Results März 12, 2026 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference März 03, 2026 at 09:30 PM UTC
Internal link ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook Januar 08, 2026 at 01:00 PM UTC
Internal link ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration Dezember 11, 2024 at 12:00 PM UTC
Internal link ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist Dezember 10, 2024 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024 Dezember 05, 2024 at 01:00 PM UTC
Internal link ProQR Announces Third Quarter 2024 Operating and Financial Results November 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement Oktober 25, 2024 at 08:45 PM UTC
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement Oktober 23, 2024 at 02:15 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares Oktober 22, 2024 at 08:01 PM UTC
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society Oktober 07, 2024 at 12:00 PM UTC
Internal link ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference September 10, 2024 at 08:30 PM UTC
Internal link ProQR Announces Second Quarter 2024 Operating and Financial Results August 08, 2024 at 11:00 AM UTC
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit Juni 18, 2024 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2024 Operating and Financial Results Mai 09, 2024 at 11:00 AM UTC
Internal link ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases Mai 08, 2024 at 12:00 PM UTC
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 April 23, 2024 at 11:00 AM UTC